Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$7.59
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.59
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.98 - $18.80
Previous CloseN/A
Volume45.37K
Average Volume (3M)106.25K
Market Cap
$197.37M
Enterprise Value$66.59M
Total Cash (Recent Filing)$143.38M
Total Debt (Recent Filing)$12.60M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Mar 05, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding26,003,607
10 Day Avg. Volume144,493
30 Day Avg. Volume106,251
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-68.21
Price to Sales (P/S)11.92
P/FCF Ratio-14.16
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue61.03
Enterprise Value/Gross Profit-5.69
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$32.67Price Target Upside330.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$672.57K
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment in the Phase III AURORA study for Descartes-08 is on track, advancing prospects for pivotal efficacy data that could support regulatory approval.
Commercial Scalability And AdministrationMRNA-based Descartes-08 can be administered outpatient without lymphodepletion and may have lower production costs, supporting broader access and easier delivery outside specialized centers.
Pediatric And Autoimmune ExpansionInitiation of the HELIOS pediatric basket study and FDA IND acceptance for myositis expand Descartes-08 development into juvenile dermatomyositis and additional autoimmune indications, increasing the potential patient pool.
Bears Say
Market Adoption And Valuation RiskPersistent severe adverse event concerns in the T-cell therapy class could reduce clinician willingness to refer patients and weigh on investor sentiment and company valuation in the space.
Regulatory ScrutinySafety signals tied to T-cell engager programs may prompt regulators to require additional monitoring or more stringent trial requirements for similar therapeutic classes, potentially lengthening development timelines.
T-cell Engager Safety RisksReported risks of CRS and ICANS and severe infections with T-cell engagers could limit uptake of T-cell–directed therapies and raise safety concerns for related treatment approaches.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.98 and its highest was $18.80 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $197.37M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Mar 05, 2026 which is in 2 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.533.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.85.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 26,003,607 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went down -1.565%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.67 (330.43% Upside)
$32.67 (330.43% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.15%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$32.67
▲(330.43% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
42.20% Insiders
8.77% Mutual Funds
2.17% Other Institutional Investors
43.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---